Milnacipran Demonstrated Significant Improvement In Pain And The Core Symptoms Of Fibromyalgia Syndrome, Data Show

Total daily dosages of milnacipran 100 mg and 200 mg demonstrated statistically significant and clinically meaningful improvements in both pain and other core symptoms associated with fibromyalgia syndrome (FMS), according to Phase III data presented this week at the 2007 American College of Rheumatology meeting in Boston, MA. The therapeutic effects of milnacipran among responders in a six-month study were sustained for up to one year in a double-blind extension trial. [click link for full article]

More: continued here

Filed under: Pain / Anesthetics on November 9th, 2007